GEN - Genetic Engineering & Biotech NewsOriginal article
Anticancer Candidate Strengthens Bones and Prevents Weight Gain in Postmenopausal Mice
Phase 1CADD522Positive
AI Analysis
Summary
Preclinical study shows CADD522, a small-molecule RUNX2 inhibitor originally developed as an anticancer candidate, protected against osteoporosis and prevented metabolic changes in postmenopausal bone loss mouse models.
Clinical Trial Data
Phase
preclinical
Primary Endpoint
Met
Importance:3/10
Sentiment:
0.60
preclinicalosteoporosispostmenopausalsmall-moleculeRUNX2 inhibitorbone healthmetabolic
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on September 8, 2026 3:48 PM